Background: The purpose of this study was to evaluate the prognostic and predictive value of p27 expression in patients with early breast cancer.
introduction
Adjuvant chemotherapy has been shown to improve breast cancer outcome [1] . Nevertheless, only a small proportion of patients benefit from such treatment, so there is a need to identify highly sensitive cases in order to avoid side-effects of cytotoxic agents [2] . Several biomarkers have been tested as predictor for the efficacy of adjuvant chemotherapy over a nonchemotherapy arm. Estrogen receptor (ER) has been reported in several cross-validating studies [3] [4] [5] as a major determinant of the sensitivity to first or second generation of adjuvant chemotherapy. In these studies, ER-poor tumors were shown to derive high benefit from adjuvant chemotherapy, although the benefit was only minor in patients with ERpositive tumors. Nevertheless, the actual predictive value of ER is matter of controversy since this finding was not confirmed in the Oxford metaanalysis [1] . Besides ER, only a few molecular predictors have been reported to predict efficacy of adjuvant chemotherapy over a nonchemotherapy arm. Her2 overexpression did not predict the efficacy of chemotherapy in several reports [3, 4] . Similar negative findings were reported with Ki-67. As illustration, no predictive value was found for Ki-67 in International Breast Cancer Study Group (IBCSG) VIII/IX studies [6] . Finally, a multigene predictor that includes ER, Her2 and Ki-67 has been reported to predict chemotherapy efficacy [7, 8] but the statistical analysis in the first study was flawed [9] and adjustment for Allred-scored ER made the interaction nonsignificant in the second study [8] ; i.e. its add value as compared with ER/Her2 assessed by immunohistochemistry is not yet proven [10] . Overall, there is a need for new molecular predictors that would be complementary to ER to predict benefit of adjuvant chemotherapy.
p27 is a nuclear protein that mediates cell cycle arrest [11] . In patients who do not receive adjuvant chemotherapy, its prognostic value is matter of debate since several papers have reported an association between p27 expression and longer survival, while some other papers failed to confirm such association [12] [13] [14] . Nuclear expression of p27 has been reported to be prognostic in patients treated with adjuvant chemotherapy [15] , giving rise to the hypothesis that this biomarker could be predictive to the efficacy of adjuvant chemotherapy. More recently, other works have reported that relocalization of p27 to the cytoplasm could also be a biomarker. Cytoplasmic p27 indeed regulates kinase stability, cell survival and motility. Such cytoplasmic expression of p27 has been correlated with prognosis in different diseases including ovarian cancers and breast cancers [11] . Based on this background [12] [13] [14] [15] , we have hypothesized that high nuclear p27 could be associated with better outcome in patients with early breast cancer. Also, based on the observation that p27 relocation regulates cell survival [16] , we hypothesized that high p27 nuclear/cytoplasmic ratio could be predictive for the efficacy of adjuvant chemotherapy. In order to address these hypotheses, we carried out p27 immunostaining and analyses on AQUA system, in a series of 823 patients with early breast cancer included in two trials testing the efficacy of adjuvant chemotherapy.
patients and methods

patients
Two French multicentric randomized trials compared adjuvant anthracycline-based chemotherapy with no chemotherapy in pre-and postmenopausal early breast cancer patients and included a total of 1146 patients, between 1989 and 1995. Nine hundred and thirty-five patients (83% of the trials) were included at the Institut Gustave Roussy (IGR). Inclusion criteria and results of these trials were reported elsewhere [16] . Of the 935 patients, 688 were postmenopausal and presented either with histologically confirmed positive axillary lymph nodes or with negative lymph nodes but a tumor grade II or III. The remaining 247 patients were premenopausal and presented with negative axillary nodes but with a tumor grade II or III. Tumor grade was defined according to a modified Scarff-Bloom-Richardson classification [17] .
tissue array and immunostaining
Primary tumors from 823 (88%) of the 935 patients included at the IGR were used to build a tissue microarray [18] . This accounts for 87% of the tumors collected, 76% of the patients included in the trials at the IGR and 63% of the overall population included in the trial. The primary tumor sample was not found for 112 of the 935 patients included at the IGR. The patients corresponding to the 112 nonretrieved tumors were significantly younger than those corresponding to the 823 retrieved tumors (mean age 54 versus 56 years, P = 0.02), less frequently postmenopausal (63% versus 75%, P = 0.01) and less frequently PR positive (54% versus 76%, P < 0.001). The tissue array contained three cores of each primary tumor. The study flowchart is reported in supplemental Figure S1 , available at Annals of Oncology online.
After deparaffinization, tissues microarrays slides were treated in NaCitrate ( pH = 6) for antigen retrieval in a pressure cooker for 10 min. Slides were blocked serially with 2.5% peroxide in methanol and 0.3% bovine serum albumin in Tris/Tween. Then, the slides were incubated overnight at 4°C with a monoclonal mouse anticytokeratin antibody (clone AE1/AE3; Dako, Carpinteria, CA, 1 : 100) and p27 Kip1 Rabbit pAb (Cell Signaling Technologies, Danvers, MA) at 1 : 20 000. Then, slides were washed in 1 × Tris-buffered saline (TBS) rinses and incubated with secondary antibodies for 1 h at room temperature as follows: Alexa 546 goat antimouse (1 : 100; Invitrogen, Eugene, OR) for detecting cytokeratin and goat antirabbit horseradish peroxidase with a dextran polymer backbone (Envision; Dako). The slides were washed with TBS rinses followed by a 10-min incubation with Cy-5 tyramide (1 : 50 dilution in Amplification Diluent; Perkin Elmer Inc., Waltham, MA) then washed three times before coverslipping with Prolong Gold mounting medium (Invitrogen).
Both nuclear and Nuclear/cytoplasmic ratio staining were considered for analyses. Quantification of nuclear and cytoplasmic p27 was done using the AQUA system (HistoRx, Inc., Branford, CT) for quantitative immunofluorescence that has been previously described [19, 20] . Illustrative stainings are shown in Figure 1 . In addition, each slide was stained with anti-Her2 (DA485; Dako), anti-ER (clone 6F11; Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK) antibodies according to manufacturer recommendations. The cut-offs used for defining positivity and the predictive values of the latter biomarkers have been previously reported [3] . Triple negative breast cancers were defined as ER-negative ( < 10% tumor cells stained), progesterone-negative ( < 10% tumor cells stained) and Her2-normal ( < 10% cells overexpressing Her2) cancers.
treatment and follow-up
The chemotherapy regimen consisted of six courses of 5-fluorouracil 500 mg/m 2 , doxorubicin or epirubicin 50 mg/m 2 and cyclophosphamide 500 mg/m 2 , administered i.v. on day 1 (D0 = D28). Locoregional treatment, endocrine therapy and follow-up have been reported elsewhere [16] . Premenopausal women did not receive any endocrine therapy. Postmenopausal women were allowed to be included in a randomized trial comparing short (2-3 years) versus long ( > 10 years) tamoxifen.
statistical analysis
The primary end point was disease-free survival (DFS), defined as the time between the date of randomization and the date of the last follow-up or the date of the best available evidence for the first event: locoregional recurrence, distant metastasis, contralateral breast tumor or death. Survival rates were estimated using the Kaplan-Meier method. The median followup was calculated by use of the inverted Kaplan-Meier method [21] . p27 expression was considered both as a continuous variable and a binary variable, with a prespecified cut-off equal to the overall median value, for analyses. The prognostic values of p27 were determined using likelihood Figure S2 , available at Annals of Oncology online.
High p27 nuclear expression correlated with positive lymph node status (P < 0.001), ER expression (P = 0.002). Low p27 nuclear expression was associated with triple negative phenotype (P < 0.001). High p27 nuclear/cytoplasmic ratio correlated with positive lymph node status (P = 0.001), ER expression (P < 0.001). Low p27 nuclear/cytoplasmic ratio correlated with HER2 expression (P = 0.008), epidermal growth factor receptor (EGFR) expression (P < 0.001), triple negative phenotype (P = 0.03) and grade (P < 0.001).
benefit of adjuvant chemotherapy in the overall population
At the date of analysis, the median follow-up time was equal to 11 years. The covariates age, ER and HER2 expressions, tumor grade and lymph node status used for multivariate analysis were assessable in 695 patients. Among them, 279 patients developed a relapse or death, and 172 patients died during the follow-up. The adjusted HR of relapse or death for patients treated with adjuvant chemotherapy was 0.81 [95% confidence interval (CI) 0.64-1.03, P = 0.08]. The adjusted HR of death for patients treated with adjuvant chemotherapy was 0.97 (95% CI 0.64-1.46, P = 0.87).
prognostic and predictive values of p27 stainings
Nuclear p27 expression as continuous variable was not predictive for the efficacy of anthracycline-based chemotherapy [test for interaction, adjusted P = 0.39 for DFS and 0.64 for overall survival (OS), Table 2 ]. In addition, nuclear p27 staining was neither prognostic for DFS (adjusted HR = 1.00, 95% CI 1.00-1.00, P = 0.63) nor for OS (adjusted HR = 1.00, 95% CI 1.00-1.01, P = 0.79). Cytoplasmic expression of p27 was not prognostic (HR = 1.00, 95% CI 1-1.01, P = 0.48) nor predictive for the efficacy of adjuvant chemotherapy (interaction test, P = 0.27) ( Table 2) .
As reported in Table 2 , p27 nuclear/cytoplasmic ratio as continuous variable was predictive for the efficacy of anthracycline-based adjuvant chemotherapy both on DFS (adjusted P value = 0.02, test for interaction) and OS (adjusted P value = 0.02, test for interaction). When dichotomized at the median, p27 nuclear/cytoplasmic ratio was predictive for the efficacy of chemotherapy for DFS (P = 0.01) but not for OS (P = 0.08). Adjusted HRs for treatment efficacy are reported in Table 2 (DFS and OS). The adjusted HR for relapse associated with adjuvant chemotherapy was 0.56 (95% CI 0.38-0.81, P = 0.002) for patients with high nuclear/cytoplasmic ratio. At the opposite, the adjusted HR for relapse associated with adjuvant chemotherapy was 1.06 (95% CI 0.78-1.46, P = 0.70) for patients with low nuclear/cytoplasmic. DFS curves according to p27 nuclear/cytoplasmic ratio and treatment are reported in Figure 2 . In order to represent the influence of continuous p27 Annals of Oncology original articles N/C ratio on the treatment effect of adding chemotherapy, we represented the chemotherapy effect in each quartile of p27 N/C ratio. As shown in Figure 3 , the higher the p27 N/C ratio, the more effective the chemotherapy. We then analyzed prognostic value of p27 nuclear/ cytoplasmic ratio in each treatment arm. When the overall population of patients was analyzed, p27 nuclear/cytoplasmic ratio continuous had no prognostic value for relapse (HR = 0.70, 95% CI 0.39-1.27, P = 0.24) nor for death (adjusted HR = 0.86, 95% CI 0.41-1.81, P = 0.69). Since p27 nuclear/ cytoplasmic ratio was associated with a significant test for interaction, we analyzed prognostic value both in the population of patients treated or not with adjuvant chemotherapy. In untreated patients (n = 338), p27 N/C ratio had no prognostic value (adjusted HR for relapse = 1.38, 95% CI 0.62-3.06, P = 0.43). In the subgroup of patients treated with adjuvant anthracycline-based chemotherapy (n = 357), p27 N/C ratio was associated with a significant prognostic value both for relapse and OS. The adjusted HR for relapse was 0.32 (95% CI 0.13-0.79, P = 0.01) and the HR for death was HR = 0.32 (95% CI 0.10-1.00, P = 0.04) in patients with high p27 N/C ratio.
discussion
In the present study, we have reported that nuclear/cytoplasmic ratio, but not nuclear expression of p27, is predictive for the efficacy of adjuvant chemotherapy. Several studies [22] [23] [24] have previously reported p27 nuclear expression could identify a subset of patients with low risk of relapse. In the present study, we failed to identify such prognostic effect for p27 nuclear expression. This data corroborate recent studies. In a population from IBCSG trial, Spataro et al. [25] did not find a significant prognostic value for p27 nuclear expression. Similarly, Kourea et al. [26] did not report a prognostic value for p27 nuclear expression in a population of 170 patients with node-negative disease treated with surgery alone. There are several hypotheses to explain lack of prognostic value for p27 nuclear expression. First, the method to quantify p27 nuclear expression was different in the present study. Indeed, the AQUA system integrates both the percentage of stained cells and their intensity. In most of the studies that reported a statistically significant association between p27 and outcome, only the percentage of tumor cells was taken into account. The second explanation could relate to treatment. In the present study, endocrine therapy was suboptimal. Indeed, none of the premenopausal patients received endocrine therapy, and around half of the postmenopausal patients received a suboptimal endocrine therapy (2-3 years tamoxifen). Biomarker studies from the Austrian Breast and Colorectal Cancer Study group [27, 28] have suggested that the good outcome associated with p27 expression could be related to its predictive value for the efficacy of endocrine therapy. In this latter study, p27 nuclear expression was prognostic only in patients treated with optimal endocrine therapy but not in those treated with chemotherapy without endocrine treatment. In the same study, 5-year RFS was 88% and 62% in patients treated with optimal endocrine therapy who presented a high and a low p27 nuclear expression, respectively. Also, in the large study reported by Porter et al. [15] , all patients with ER-positive disease received 5-year tamoxifen. In this latter study, the expression of p27 was prognostic in patients with ER-positive but not in ER-negative disease. The most striking data from the present study were the finding that p27 nuclear/cytoplasmic ratio was predictive for the efficacy of adjuvant chemotherapy. The p27 relocation in cytoplasm is induced by kinase activation, including PKB/AKT activation [29] . The present study corroborates well these findings by showing that p27 nuclear/cytoplasmic ratio is associated with tyrosine kinase expressions (Her2, EGFR). The mechanism that leads to higher sensitivity to chemotherapy in patients with high p27 N/C ratio is unclear. Nevertheless, several hypotheses can be drawn from the preclinical studies. First, several data suggest that topoisomerase IIa inhibitors could arrest cell cycle through the increase of nuclear p27 [30] . The implication of such finding could be that the high rate of mislocated p27 could prevent upregulation of nuclear p27 by topoisomerase IIa inhibitors. Also, high cytoplasmic p27 has been shown to mediate cell survival. In a study by Wu et al. [29] , the transfection of cytosolic p27 was associated with a decreased apoptosis. These data suggest that high cytosolic p27 
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and therefore low N/C ratio could be associated with a resistance to cytotoxic-induced apoptosis. The mechanisms that lead to high chemosensitivity are currently under investigation.
Although the present study reports significant interaction between p27 nuclear/cytoplasmic ration, it presents several limitations. First, the statistics were not adjusted for multiple hypothesis testing. Second, the endocrine therapy was suboptimal and therefore does not allow concluding about the potential value of p27 to predict relapse in patients treated with contemporary endocrine therapy. Finally, the chemotherapy was suboptimal since patients received low-dose anthracyclines. Overall, these considerations suggest that treatment used in the present study are not representative of the contemporary therapies and emphasize the need for validation in modern series of patients. Overall, the present study fails to confirm a prognostic value for nuclear p27 expression but suggests that the nuclear/cytoplasmic ratio could predict the efficacy of adjuvant chemotherapy in breast cancer. Ongoing preclinical studies aim at defining the mechanism of resistance associated with a low nuclear/ cytoplasmic ratio and future studies are being considered for validation of the p27 ratio. 
